-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Meeting News
-
Second Presidential Symposium to Focus on Latest in Targeted Therapy Research
Presentations will include data from the POLESTAR, SOHO-01, Beamion LUNG-1, FURTHER, and FLOWERS trials.
-
Challenging Patient Outcomes Can Cause Oncologists to Question Their Skills
During a Health & Wellbeing session, Dr. Mark Lewis will offer strategies for navigating such situations.
-
Meet the Expert: Radiological Challenges in Lung Cancer
Dr. Ioannis Vlahos will address issues radiologists encounter in applying TNM staging guidelines in daily practice.
-
Self-Learning AI as a Diagnostic Tool in Malignant Mesothelioma
Prof. John Le Quesne will show how AI can be used to subtype mesothelioma into risk categories and prognosis.
-
IASLC Journals See Continued Success Throughout Past Year
Editors-in-Chief Drs. Alex A. Adjei and Emily Stone will talk with members during a Meet-the-Editor session on Monday afternoon.
-
Hands-on Workshop Outlines Challenges and Potential Solutions for Translating Early Detection Biomarkers From Discovery to Lung Cancer Clinical Practice
An expert panel from the US National Cancer Institute’s Early Detection Research Network provided insights into the current state of the art as well as barriers to use.
-
Updated Biomarker Survey Results Show Paradigm Shift As More Respondents Now Consider Testing a “Must Have”
However, lead author Dr. Matthew Smeltzer said the new data also show clinicians value biomarker testing more in late-stage disease compared to early-stage disease.
-
9th Edition Lung Cancer Staging Recommendations to be Explained
During the session, experts will not only review the updates, they will also discuss how they approached the process and the guidelines’ limitations.
-
Special Plenary to Focus on IASLC’s Role in Shaping Thoracic Cancer Research, Treatment
Former IASLC CEO Dr. Paul A. Bunn, Jr., says lung cancer is a global challenge and the unique multinational and multi-specialty nature of the IASLC has helped to build a global response.
-
Learn and Network During Poster Viewing Events
The WCLC 2024 program includes several opportunities to browse posters and see the latest in thoracic oncology research.